Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
A Phase 1, Study of VX-828 in Healthy Subjects and in Subjects With Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
255 participants
Dec 12, 2023
INTERVENTIONAL
Conditions
Summary
The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/ deutivacaftor (D-IVA) in healthy participants and VX-828 in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).
Eligibility
Inclusion Criteria12
- Parts A-D:
- Participants between the ages of 18 and 55 years
- Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
- A total body weight of more than (\>) 50 kg
- Nonsmoker or ex-smoker for at least 3 months before screening with current nonsmoking status confirmed by urine or blood cotinine at screening
- Cohort C2 only: Willing to provide a single DNA sample
- Part E:
- Participants 18 years or older
- Confirmed diagnosis of CF as determined by the investigator
- A total body weight of more than or equal to (\>=) 35 kg
- Participants must be heterozygous for F508del with a second CFTR allele carrying a minimal function mutation that is not responsive to ELX/TEZ/IVA therapy
- Participants must have a forced expiratory volume in 1 second (FEV1) of greater than or equal to (≥) 40% of predicted normal for age, sex, and height
Exclusion Criteria8
- Parts A-D:
- History of febrile illness or other acute illness within 14 days before the first dose of study drug
- Any condition possibly affecting drug absorption
- Part E:
- An acute illness not related to CF (e.g., gastroenteritis) within 14 days before the first dose of study drug
- History of solid organ or hematological transplantation
- History of clinically significant cirrhosis with or without portal hypertension
- Lung infection with organisms associated with a more rapid decline in pulmonary status
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Suspension for Oral Administration
Suspension for Oral Administration
Solution for Oral Administration
Syrup for Oral Administration
Tablets for Oral Administration
Tablets for Oral Administration
Suspension and Tablets for Oral Administration
Tablets for Oral Administration
Tablets for Oral Administration
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06154447